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I. INTRODUCTION
The United States is one of the only countries in the world that allows direct-toconsumer (DTC) advertisement of pharmaceuticals and medical devices.1 The
United States Food and Drug Administration (FDA) regulates all prescription drug
advertising—to medical professionals and consumers—and promotional labeling.2
DTC advertisements are directed to consumers rather than healthcare providers, and
include, broadcast (e.g., television), print (e.g., newspaper), and internet (e.g., website)
advertisements. In contrast, promotional labeling includes brochures or pamphlets that
medical professionals provide to consumers or other non-healthcare providers.
DTC advertising has become an increasingly important topic because a growing number
of Americans, across various populations and demographics, are looking online for
health information,3 and they are looking primarily to “learn more about” their disease
or condition.4 In 2010, eighty-nine million adults in the United States tapped into social
media resources for health-related purposes, compared with sixty-three million in
2008 and thirty-eight million in 2007.5 Moreover, fifty-nine percent of non-physician
healthcare professionals who work directly with and on behalf of patients indicated that

Mr. Gitterman is admitted only in Pennsylvania and New Jersey. He is practicing law in the District
of Columbia during the pendency of his application for admission to the D.C. Bar and under the
supervision of lawyers who are members in good standing of the D.C. Bar. The content of this
article is intended for informational purposes only. It is not intended to solicit business or to provide
legal advice. The opinions expressed are those of the author and do not necessarily reflect the views
of the firm or its clients.
1

U.S. Food and Drug Admin., Keeping Watch Over Direct-To-Consumer Ads, FDA.gov (Aug. 19,
2013), http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm107170.htm [hereinafter Watch
Over DTC Ads]. New Zealand is the only other developed nation that permits DTC advertising of
drugs and medical devices. Id.
2

U.S. Food and Drug Admin., Drug Advertising: A Glossary of Terms, FDA.gov (Sept. 13, 2012),
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm072025.
htm#promotional_labeling [hereinafter FDA Glossary] (defining promotional labeling as having
the same purpose as advertising to sell prescription drugs but as being effectuated through different
mediums).
3

Richard Meyer, Is ROI A Roadblock to New DTC Marketing Initiatives?,
WorldOfDTCMarketing.com (Oct. 12, 2012), http://worldofdtcmarketing.com/is-roi-a-roadblockto-new-dtc-marketing-initiatives/business-of-the-drug-industry/ (noting that 72% of 18–29 yearolds; 71% of 30–49 year-olds; and 46% of 50 individuals and older use the internet to research
health questions).
4

Engaging E-Patients In Dialogue, WorldOfDTCMarketing.com (last visited Mar. 24, 2014),
http://worldofdtcmarketing.com/wp-content/uploads/2012/10/Engaging-epatients-in-dialogue.jpg
(explaining that 36% of patients visit online health communities to learn more about their disease)
5

Richard Meyer, Sanofi-Aventis Blazes Social Media Trails, WorldOfDTCMarketing.com
(Aug. 21, 2012), http://worldofdtcmarketing.com/sanofi-aventis-blazes-social-media-trails/socialmedia-and-healthcare/ (noting that consumers turn to each other on social media due to distrust of
advertisers); see also Nat’l Research Corp., 1 In 5 Americans Use Social Media for Health Care
Information, NationalResearchCorporation.com (Feb. 28, 2011), http://hcmg.nationalresearch.
com/public/News.Aspx?ID=9 (discussing the increasing influence of social media on Americans
seeking healthcare information).
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patients “often or sometimes bring information from the internet to discuss.”6 While
pharmaceutical and medical device manufacturers7 have decreased spending on DTC
television advertisements in recent years,8 digital advertising budgets were expected to
reach fifteen percent in 2012 and twenty percent in 2013 out of total marketing budget,
with big increases expected in “social media initiatives for consumers.”9 While declines
in internet DTC spending were actually seen in 2013 by almost fifteen percent, this
can be attributed to the lack of FDA guidance and manufacturers “well-known anxiety
around all things ‘e,’ media.”10
There are both proponents and opponents of the use of DTC advertising by drug and
device companies. Proponents of DTC advertisements argue that they (1) provide useful
information to consumers that may result in better health;11 (2) advance public health
by encouraging more people to talk with healthcare professionals about problems,
particularly under-treated, under-diagnosed conditions, such as high blood pressure;12
(3) help remove the stigma associated with certain diseases (e.g., depression); and
(4) remind patients to refill prescriptions and help them adhere to their medication
regimens.13 Critics maintain that such advertisements are troublesome because they (1)
may contain false or misleading information; (2) do not provide enough information
6

Patient Ed: How Patients Learn In the Digital Age, WorldOfDTCMarketing.com (last visited
Mar. 24, 2014), http://worldofdtcmarketing.com/wp-content/uploads/2013/02/HealthEd-AcademyHow-Patients-Learn.jpg (finding that non-MDs who work with and on behalf of patients use online
videos like YouTube to educate their patients (44%), as well as blogs (18%), and patients themselves
print out online materials to use patient visits (55%)).
7

Pharmaceutical and medical device manufacturers, manufacturers, or companies may be used
interchangeably throughout this paper to signify entities that manufacture or produce FDA regulated
pharmaceuticals, biologics, medical devices, or medical supplies.
8

Bruce Japsen, Drug Makers Dial Down TV Advertising, NYTimes.com, Feb. 2, 2012, http://
prescriptions.blogs.nytimes.com/2012/02/02/drug-makers-dial-down-tv-advertising/?_php=true&_
type=blogs&_r=0.
9

Richard Meyer, Digital Budget for Pharma Expected To Be 20% for 2013,
WorldOfDTCMarketing.com (Oct. 30, 2012), http://worldofdtcmarketing.com/digital-budgetfor-pharma-expected-to-be-20-for-pharma/business-of-the-drug-industry/. See also Matt Kapko,
Pharma and Healthcare Drive Biggest Online Ad Spending Gains, ClickZ.com (Oct. 11, 2012),
http://www.clickz.com/clickz/news/2216594/pharma-and-healthcare-drive-biggest-online-adspending-gains.
10

Larry Dobrow, DTC Report: DTC Gets Smart, Medical Marketing & Media (Apr. 1, 2014)
available at http://www.mmm-online.com/dtc-report-dtc-gets-smart/article/339357/.
11

Branded Pharmaceutical Websites Continue to Generate Highest Lifts in Rx Conversion
and Adherence, comScore.com (Apr. 5, 2012), http://www.comscore.com/esl/Insights/Press_
Releases/2012/4/Branded_Pharmaceutical_Websites_Continue_to_Generate_Highest_Lifts
(determining that existing patients of a drug brand who visited the brand site increased their refill
rate by 14.7% and also saw an 8.9% increase in beginning treatment compared to those with no
exposure to the site).
12

U.S. Food and Drug Admin., Guidance for Industry: “Help-Seeking” and Other Disease
Awareness Communications By or On Behalf Of Drug and Device Firms: Draft Guidance, FDA.gov
(Jan. 23, 2004), http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm070068.pdf [hereinafter FDA Help-Seeking Guidance] (listing also depression,
hyperlipidemia, hypertension, and diabetes as under-treated, under-diagnosed illnesses).
13

Watch Over DTC Ads, supra note 1.

One Click Away From Untangling the Web

7

about the risks and negative effects of certain treatments; (3) may not advance—and
may even threaten—public health; (4) encourage overuse of prescription drugs; and (5)
encourage use of costly treatments, instead of less expensive treatments that may be
equivalent, raising healthcare costs.14
Despite concerns regarding DTC advertising, the FDA recognizes that drug and
device advertisements “can provide useful information for consumers to work with
their healthcare professionals to make wise decisions about treatment.”15 Moreover,
removing DTC advertisements could “affect public health” by leaving people who
would benefit from a new drug or device unaware of its availability, causing them not to
seek treatment in absence of such advertising.16 While the FDA has the jurisdiction to
regulate online DTC advertisements, an increase in the number of materials submitted,
coupled with a significant number of new online platforms, has made the FDA’s job of
review and enforcement with regards to such materials very difficult.17
The rate at which technology and social media or interactive promotional media18
develops continues to surpass FDA’s ability to stay up-to-date with the various ways
in which companies are using such platforms for promotion. There are numerous
types of interactive promotional media, including blogs,19 microblogs,20 podcasts,21
video sharing,22 widgets,23 wikis,24 social networking sites,25 content communities,
collaborative projects, and virtual social or game worlds. Moreover, more than fifty
percent “of leading pharma[ceutical] companies expect social networking, [podcasts,]
online video and other types of digital marketing to grow in use as critical tools for
communicating disease state and product information.”26 To satisfy FDA’s statutory
14

Id.

15

Id. See also FDA Help-Seeking Guidance, supra note 12.

16

Shelia Campbell, Potential Effects of a Ban on Direct-to-Consumer Advertising of New
Prescription Drugs, CBO.gov (May 26, 2011), http://www.cbo.gov/publication/42186.
17

Thomas Sullivan, Policy Updates and Enforcement Developments From FDA’s Medical
Products Centers: Tips on Social Media, Policy and Medicine (Dec. 22, 2011, 5:28 AM), http://
www.policymed.com/2011/12/policy-updates-and-enforcement-developments-from-fdas-medicalproducts-centers-tips-on-social-media.html.
18

These words may be used interchangeably throughout this article but are meant to indicate the
use of any interactive online platform that allows for real-time communications and interactions
(e.g., Facebook, YouTube, Twitter, Instagram, etc.).
19

Promotion of Food and Drug Administration-Regulated Medical Products Using the Internet
and Social Media Tools; Notice of Public Hearing, 74 Fed. Reg. 48,083-01, 48,085, Sept. 21, 2009
[hereinafter FDA Social Media Hearing Notice]. Web logs, or “blogs,” are generally informal
journal-type updates that encourage dialog about a subject. Id. at 48,085.
20

Id. A “microblog” is similar to a blog but much shorter. Id. Twitter is a microblog service. Id.

21

Id. Podcasts are video or audio clips that users can listen to or watch from a remote location. Id.

22

Id. Video sharing allows the public to upload video clips to the internet (e.g.,YouTube). Id.

23

Id. Widgets are a graphic control on a Web page that allows the user to interact with it. Id.
Widgets can be posted on multiple sites, host ‘live’ content, and are often on-screen tools. Id.
24

Id. Wikis are webpages that anyone with access can modify (e.g., Wikipedia). Id.

25

Id. Social networks allow users to connect with others (e.g., Facebook and LinkedIn). Id.

26

Tanya Irwin, Pharma Jumps On Social Media Bandwagon, MediaPost (Oct. 29, 2012), http://
www.mediapost.com/publications/article/186133/pharma-jumps-on-social-media-bandwagon.html.

8
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obligation to issue social media guidance by July 9, 2014,27 the Agency released its
“first” guidance in January 2014, entitled “Draft Guidance for Industry: Fulfilling
Regulatory Requirements for Postmarketing Submissions of Interactive Promotional
Media for Prescription Human and Animal Drugs and Biologics” (“Guidance”).28 While
this guidance primarily focuses on how manufacturers can fulfill their post-marketing
submission requirements for interactive promotional media, the FDA’s overall approach
to interactive promotional media may provide useful insight for industry and stakeholders
about the concerns noted above, and what the FDA’s interactive promotional media
regime may hold in the near future.
This article analyzes several issues for the FDA and manufacturers to consider in
finalizing the post-marketing guidance and drafting future interactive promotional
media guidance, which the Agency has already announced.29 Part II provides a brief
history of the FDA’s regulation of DTC advertisements. Parts III and IV discuss the
FDA’s oversight and enforcement with regards to such advertisements. Parts V and
VI examine the difficulties posed by internet and social media advertisements, and
examines several current examples of such advertisements. Finally, Part VII proposes
several recommendations for consideration by the FDA and industry when promulgating
guidance.

II. HISTORY OF DTC ADVERTISING AND PROMOTION
The Pure Food and Drugs Act of 190630 was one of Congress’ first attempts to regulate
prescription drugs, however, the legislation only contained provisions about product
labels.31 In addition, the Federal Trade Commission (FTC) “did not have the authority
to regulate deceptive advertisements unless it could prove that such advertisements
injured another company.”32 To address this gap in regulation, Congress replaced the
1906 Act with the Federal Food, Drug, and Cosmetic Act of 1938 (FDCA).33 The
27

Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, § 1121, 126 Stat.
993, 1112 (2012) [hereinafter FDASIA].
28

U.S. Food and Drug Admin., Guidance for Industry: Fulfilling Regulatory Requirements
for Postmarketing Submissions of Interactive Promotional Media for Prescription Human
and Animal Drugs and Biologics, FDA.gov (Jan. 2014), www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM381352.pdf. [hereinafter FDA PostMarketing Interactive Promotional Media Guidance].
29

U.S. Food and Drug Admin., Guidance Agenda: New & Revised Draft Guidances CDER is
Planning to Publish During Calendar Year 2014, FDA.gov (Jan. 31, 2014), http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM314767.pdf.
These include: (1) Internet/Social Media Platforms with Character Space Limitations: Presenting
Risk and Benefit Information for Prescription Drugs and Medical Devices; (2) Internet/Social
Media Platforms: Correcting Independent-Third Party Misinformation About Prescription Drugs
and Medical Devices; and (3) Internet/Social Media Advertising and Promotional Labeling of
Prescription Drugs and Medical Devices – Use of Links. Id.
30

Pure Food and Drugs Act of 1906, Pub. L. No. 59-384, 34 Stat. 768 (1906) (repealed 1938).

31

Francis B. Palumbo & C. Daniel Mullins, The Development of Direct-to-Consumer Prescription
Drug Advertising Regulation, 57 Food & Drug L. J. 423, 424-25 (2002).
32

Id. at 425.

33

Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (as amended 21
U.S.C. §§ 301 et seq.).
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passage of the FDCA was necessary because among other things, the United States
had seen a significant evolution of advertising practices such as radio, and the use of
drug and cosmetic advertisements in magazines and newspapers since 1906.34 The final
legislation, however, only granted the FDA jurisdiction over the labeling of all drugs
and omitted advertising provisions. Instead, “Congress amended the Federal Trade
Commission Act in 1938 to give jurisdiction over all drug advertising to the FTC.”35
In 1962, “the Kefauver-Harris Drug Amendments to the FDCA transferred regulatory
authority over prescription drug advertising from the FTC to the FDA, by enacting section
502(n).”36 Although the FDA promulgated detailed drug advertisement regulations a
year later, in 1963, the promulgated regulations were designed for promotions directed
to physicians.37 This was unsurprising, however, because Congress did not intend for
the FDA to regulate drug advertisements to consumers and such advertisements barely
existed in 1962.38 Thus, under the FDCA, the FDA has responsibility for regulating
the FDA-approved labeling,39 promotional labeling,40 and advertising for prescription
drugs. Section 201(m) of the Act, defines labeling to include all “written, printed,
or graphic” materials “accompanying” a regulated product.41 The FDA argues that
although this definition of labeling is not limited to materials that physically accompany
a product the textual relationship between the materials and the product is fundamental,
and the Supreme Court agrees with this position.42
The FDCA “does not specifically define” prescription drug “advertising” or
“advertisement,” but the FDA generally interprets the term to “include information
(other than labeling) that is sponsored by a manufacturer and is intended to supplement
or explain a product.”43 If a promotional activity or material is considered advertising or
labeling, the activity or material must contain adequate directions and information for
34

Palumbo, supra note 31, at 425 (citation omitted).

35

Id. at 426 (citing Wheeler-Lea Act, 52 Stat. 111, ch. 49 (1938)).

36

Id. Prior to the 1962 Amendments, the FDA and the FTC had entered into a “Working
Agreement” in 1954.
37

Lars Noah, Advertising Prescription Drugs to Consumers, 32 Ga. L. Rev. 141, 142 (1997).

38

See H.R. Rep. No. 87-2464, at 2 (1962) (describing as one of the principal purposes of the
legislation . . . to make available “adequate information concerning safety and effectiveness of drugs
advertised to physicians”).
39

FDA Help-Seeking Guidance, supra note 12.

40

Id. Promotional labeling is generally any labeling other than the FDA-approved labeling. Id.

41

21 U.S.C. § 321(m) (2012). The FDA regulations define advertising subject to regulation to
include“[b]rochures, booklets, mailing pieces, detailing pieces, file cards, bulletins, calendars,
price lists, catalogs, house organs, letters, motion picture films, film strips, lantern slides, sound
recordings, exhibits, literature, and reprints and similar pieces of printed, audio, or visual matter
descriptive of a drug and references published (for example, the Physicians Desk Reference) for
use by medical practitioners, pharmacists, or nurses, containing drug information supplied by the
manufacturer, packer, or distributor of the drug and which are disseminated by or on behalf of its
manufacturer, packer, or distributor . . . .” 21 CFR § 202.1(l)(2) (2013). See also V.E. Irons, Inc. v.
United States, 244 F.2d 34, 39 (1st Cir. 1957).
42

Kordel v. United States, 335 U.S. 345, 349–350 (1948).

43

Direct-to-Consumer Promotion; Public Hearing, 60 Fed. Reg. 42,581-01, 42,581 (Aug. 16, 1995)
[hereinafter 1995 DTC Hearing]. This includes, “advertisements in published journals, magazines,
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use that are the “same in language and emphasis” as the product’s approved labeling.44
This requirement can be fulfilled by including the product’s full approved labeling (the
“package insert”) with the promotional material.45
Section 352(n) of the FDCA requires drug advertisements, in written or electronic form,
to contain the brand name, list of ingredients, and a “brief summary” of side effects of
the drug.46 The brief summary must provide all of the drug’s side effects or risks listed
in the drug’s FDA-approved prescribing information (PI), contraindications, warnings,
precautions, and indications for use.47 The FDA regulations also established the “fair
balance doctrine,” which provides that the entire advertisement must present a balanced
account of all clinically relevant information.48 A drug’s risks must be presented
prominently and legibly so that the advertisement does not put more emphasis on the
drug’s benefits than its risks.49 Additionally, a drug is misbranded if its advertising is
“false or misleading, fails to reveal material facts, or fails to present a fair balance of
information.”50
III. FDA Regulation of Prescription Drug Advertising
The FDA first addressed DTC promotion of pharmaceuticals in the mid-1970s by
“issuing a regulation that authorized advertising of prescription drug prices to consumers
so long as a company made no representations about the safety or effectiveness of the
product,”51 but was “shocked” by the rise of DTC advertisements in the 1980s.52 In
1981, Boots Pharmaceuticals issued the first DTC prescription drug advertisement
in the United States for Rufen, an anti-arthritis drug.53 A 1982 speech by the FDA
Commissioner, Arthur Hull Hayes, Jr. predicting the “exponential growth” in DTC
advertisements, was seen by the industry as evidence that the FDA would permit such

other periodicals, and newspapers, and advertisements broadcast through media such as radio,
television, and telephone communication systems.” Id.
44

21 U.S.C. § 352(f) (2012); see also 21 CFR § 201.100(d) (2013).

45

1995 DTC Hearing, supra note 43.

46

21 U.S.C. § 352(n) (2012) (a drug is misbranded “unless the manufacturer . . . includes in all
advertisements . . . [a] brief summary relating to side effects, contraindications, and effectiveness as
shall be required in regulations. . . .”).
47

21 C.F.R. § 202.1(e) (2013). This information includes: (1) who should not take the drug; (2)
when the drug should not be taken; (3) possible serious side effects, and if known, what can be done
to lower the chances of having them; and (4) frequently occurring, but not necessarily serious side
effects.
48

FDA Glossary, supra note 2.

49

See 21 C.F.R. § 202.1(e)(5)-(7) (2013). For example, the risks should not appear in much smaller
type than the benefits and be placed in a corner of the advertisement far from the benefits because
they are likely to be overlooked.
50

Noah, supra note 37, at 145 (citing 21 C.F.R. § 202.1(e)(5) (1997)).

51

Id. at 147; see also Virginia State Bd. of Pharmacy v. Virginia Citizens Consumer Council, Inc.,
425 U.S. 748, 762–70 (1976).
52

Wayne L. Pines, A History and Perspective on Direct-to-Consumer Promotion, 54 Food & Drug
L. J. 489, 491 (1999).
53

Palumbo, supra note 31, at 424 (citation omitted).
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advertisements, and consequently, the FDA received “a large influx of proposed DTC
ad[vertisements].”54
Due to uncertainty regarding how to regulate DTC advertisements, the FDA issued a
formal request to industry in September 1982 “for a voluntary moratorium on DTC
advertisements, to allow FDA time to research the issue.”55 During the moratorium, the
FDA sponsored a series of public meetings and conducted several studies on the effects
of DTC advertisements.56 In September 1985, FDA removed the moratorium stating
that DTC advertisements must meet the same legal requirements as those directed at
physicians.57 Despite the FDA’s recognition that there were differences between the
expertise and knowledge of healthcare professionals and consumers as recipients of
drug promotion,58 the FDA maintained that pre-existing regulations governing drug
advertisements would sufficiently safeguard consumers. Thus, DTC advertisements had
to be fairly balanced and meet the brief summary requirements.
Companies, however, started to expand the types of DTC advertisements that they
produced. As a result, FDA recognized three broad categories of advertisements: (1)
reminder advertisements,59 (2) help-seeking or disease-oriented advertisements,60
and (3) product-claim or indication advertisements. Reminder and help-seeking
advertisements are exempt from the brief summary and fair balance requirements
because they do not reveal a drug’s risks or benefits.61 Most DTC promotions are productclaim advertisements, which must identify the drug’s brand and generic names and
accurately state an FDA-approved use for the drug.62 The product claim advertisement
must present the benefits and risks of a drug in a balanced fashion,63 and should say
that the drug is given by prescription only. While the distinction between advertisement
types was useful to the FDA and drug or device companies, the tremendous growth in
the use of DTC advertisements demanded more guidance from the Agency.

54

Pines, supra note 52, at 492.

55

Palumbo, supra note 31, at 424.

56

See Louis A. Morris & Lloyd G. Millstein, Drug Advertising to Consumers: Effects of Formats
for Magazine and Television Advertisements, 39 Food Drug Cosm. L. J. 497 (1984).
57

Direct-to-Consumer Advertising of Prescription Drugs; Withdrawal of Moratorium, 50 Fed. Reg.
36,677-02 (Sept. 9, 1985).
58

1995 DTC Hearing, supra note 43.

59

Id. Reminder advertisements call attention to the name of the drug product, but do not include
specifications or the drug’s use. Id.
60

Id. Help-seeking advertisements describe the symptoms of a disease or condition, but must not
reference a specific drug. Id.
61

FDA Glossary, supra note 2. A benefit is help provided by a drug for the person who is taking it.

Id.
62

U.S. Food and Drug Admin., Product Claim Ad (Correct), FDA.gov (Sept. 13, 2012), http://
www.fda.gov/Drugs/ResourcesForYou/Consumers/PrescriptionDrugAdvertising/ucm082284.htm.
63

FDA Glossary, supra note 2. A claim says something about the advertised drug or what it does.

Id.

12
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i. FDA DTC Advertising Guidance
Reliance on pre-existing drug advertisement regulations created “confusion among
consumers”64 and several problems for manufacturers pursuing DTC broadcast
advertisements. The FDA asked manufacturers in a July 1993 letter to voluntarily
submit proposed DTC materials prior to use, providing the FDA with an opportunity to
review and comment upon proposed materials before they reached consumers.65 Two
years later, FDA convened a public hearing to address the difficulties posed by new
communication technologies.66 At the time, broadcast advertisements were required to
contain a brief summary, unless “adequate provision [was] made for dissemination” of
the approved labeling in connection with the presentation.67 While companies could
meet this requirement for healthcare providers by “providing the page number for
the advertised product in the Physicians’ Desk Reference (PDR), along with a tollfree telephone number” to request a copy of the prescribing information (PI), this was
inadequate for most consumers. It was also impractical for a thirty-second television
advertisement to contain a brief summary because it would take minutes for the
summary to play or scroll down a television screen. As a result of this issue, companies
used mostly reminder and help-seeking advertisements on television, which were
exempt from the brief summary and fair balance requirements.68
Once manufacturers started using the internet for DTC advertising, issues arose,
prompting consumer groups, medical associations, and even some manufacturers to
ask the FDA to adopt more comprehensive regulations.69 As a result, the FDA held a
series of meetings with manufacturers in 1995 and convened an Internet Conference
in October 1996 to help guide the Agency in making policy decisions regarding the
promotion of drugs on the internet.70 The FDA, however, issued its first warning
letter prior to the 1996 Internet Conference and began targeting websites that used
improper drug promotion, “sweeping” approximately 1,200 internet websites in search
of deceptive health claims.71 Shortly thereafter, the FDA finalized guidance regarding
DTC broadcast advertisements, which recognized a distinction between print and
broadcast advertisements.72

64

Pines, supra note 52, at 496.

65

FDA Form 3439, Interim Form for Application to Market a New Drug, Biologic, or Antibiotic
Drug for Human Use; Availability, 61 Fed. Reg. 24313-02 (May 14, 1996).
66

FDA Public Hearing on Direct-to-Consumer Promotion (Oct. 18-19, 1995); see also 1995 DTC
Hearing, supra note 43.
67
68

21 C.F.R. § 202.1(e)(1) (2013).
1995 DTC Hearing, supra note 43.

69

Leah Brannon, Regulating Drug Promotion on the Internet, 54 Food & Drug L. J. 599 (1999)
(citation omitted).
70

FDA Social Media Hearing Notice, supra note 19.

71

Brannon, supra note 69, at 601 (citation omitted).

72

U.S. Food and Drug Admin., Guidance for Industry, Consumer-Directed Broadcast
Advertisements, FDA.gov (Aug. 1999), http://www.fda.gov/RegulatoryInformation/Guidances/
ucm125039.htm. [hereinafter 1999 DTC Broadcast Guidance]. See also 21 C.F.R. § 202.1(e)(1)
(2013) (regulating print and broadcast advertisements differently).
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While print advertisements must include the brief summary, broadcast advertisements
must disclose the product’s major risks in either the audio or audio and visual portions
of the presentation—known as the “major statement.”73 The amount and type of
included risk information will vary by drug because each drug has different risks.
Sponsors of broadcast advertisements are also required to present a brief summary or
make “adequate provision . . . for dissemination of the approved or permitted package
labeling in connection with the broadcast presentation.”74 Thus, the regulations specify
that the major statement, together with adequate provision for dissemination of the
drug’s approved labeling, can fulfill the mandated risk information disclosure.75
In February 2004, the FDA published several draft guidance documents pertaining to
DTC advertisements.76 The documents provide recommendations and factors industry
should consider when creating help-seeking and disease awareness advertisement,
and disclosing risk information in the brief summary in print advertisements. In 2007,
Congress passed the Food and Drug Administration Amendment Act (FDAAA), which
included Section 901, requiring that the major statement relating to side effects and
contraindications in broadcast advertisements be presented in a clear, conspicuous, and
neutral manner.77 In addition, Section 906 requires advertisements to include a specific
statement and contact information that encourages consumer reporting of negative side
effects to the FDA.78 Two years later, the FDA issued further guidance that outlined
several factors that the FDA would consider when evaluating the presentation of risk
information in DTC advertisements. These factors include (1) the amount of information
conveyed by a promotional piece; (2) materiality and comprehensiveness; (3) the nature
of benefit claims; and (4) format.79 The guidance also provides recommendations
73

1999 DTC Broadcast Guidance supra note 72.

74

Id. Broadcast advertisements must reference: (1) directions to contact a healthcare professional;
(2) a toll-free telephone number; (3) the current issue of a magazine that contains a print
advertisement; and (4) a website address. Id.
75

Id. at 2 (citing Section 502(n) of the FDCA).

76

See FDA Help-Seeking Guidance, supra note 12. See also U.S. Food and Drug Admin.,
Draft Guidance for Industry: Brief Summary: Disclosing Risk Information in ConsumerDirected Print Advertisements, FDA.gov (Jan. 2004), http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm069984.pdf. The third draft guidance
addressed medical devices, not covered in this paper.
77

U.S. Food and Drug Admin., Draft Guidance for Industry: Direct-to-Consumer Television
Advertisements – FDAAA DTC Television Ad Pre-Dissemination Review Program, FDA.gov, 1–2
(March 2012), http://www.fda.gov/downloads/Drugs/Guidances/UCM295554.pdf [hereinafter FDA
TV Pre-dissemination Guidance].
78

U.S. Food and Drug Admin., Report to Congress: DTC Advertising’s Ability to Communicate
to Subsets of Population; Barriers to Participation of Population Subsets in Clinical
Trials, FDA.gov, 4 (Sept. 2009), http://www.fda.gov/downloads/RegulatoryInformation/
Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/
FoodandDrugAdministrationAmendmentsActof2007/FDAAAImplementationChart/UCM213016.
pdf [hereinafter FDA 2009 Rept. to Congress].
79

U.S. Food and Drug Admin., Draft Guidance for Industry: Presenting Risk Information in
Prescription Drug and Medical Device Promotion, FDA.gov, 10 (May 2009), http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM155480.pdf
[hereinafter FDA Risk Information Guidance].
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regarding the use of text that is “superimposed on other images in videos or broadcast
ad[vertisement]s (SUPERs) and other visual components, such as graphics, within an
ad[vertisement]” that may be applicable to DTC advertisements online or in social
media.80
In 2012, the FDA issued draft guidance to clarify “the requirements for product
name placement, size, prominence, and frequency in promotional labeling” and drug
ad[vertisment]s.”81 The guidance pertains to product names in “electronic and computerbased promotional labeling and advertisements, such as Internet promotion, social media,
e-mails, CD-ROMs, and DVDs.”82 In addition, the guidance recognizes that electronic
and computer-based media do not contain text pages like print media, but do contain
“running text[83] equivalent to many pages of traditional printed text.”84 Although the
guidance is not specific to DTC advertisements, it provides practical recommendations
that may be applicable to social media and internet DTC advertisement.
ii. FDA’s Off-Label Guidance
In late 2011, the FDA released draft guidance regarding industry’s use of websites and
emerging electronic media to respond to unsolicited requests for off-label information.85
The guidance, however, was not the social media and internet guidance that industry
had long awaited.86 Nevertheless, the FDA provided examples in the guidance of
what might constitute solicitation by a manufacturer through social media, including:
“(1) [t]weeting study results and suggesting that an off-label use is safe and effective;
(2) [e]stablishing standard response websites that in part include off-label information;
(3) [e]ncouraging third-party bloggers to post about off-label use; (4) [c]reating a
username, e-mail address, or URL that suggests off-label use; or (5) [r]equesting users
to post videos about their product experience on a site such as YouTube, resulting in
videos on off-label use.”87 The examples provided by FDA demonstrate that the Agency

80

See id. at 18. Factors include: (1) not presenting words in all upper case; (2) using competing or
unrelated SUPERs; (3) using busy scenes, frequent scene changes, or vivid and compelling visuals;
or (4) length of time a SUPER is on a screen.
81

U.S. Food and Drug Admin., Draft Guidance: Product Name Placement, Size, and Prominence
in Advertising and Promotional Labeling, FDA.gov, 1 (January 2012), http://www.fda.gov/
downloads/Drugs/.../Guidances/ucm070076.pdf [hereinafter FDA Ad and Promotional Guidance].
82

Id. at 2.

83

Id. at 3 (noting that FDA interprets the running text “to mean the body of text in a piece, as
distinct from headlines, taglines, logos, footnotes, graphs, or pictures”).
84

Id. at 5.

85

U.S. Food and Drug Admin., Draft Guidance: Responding to Unsolicited Requests for Off-Label
Information About Prescription Drugs and Medical Devices, FDA.gov (Dec. 2011), http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM285145.pdf
[hereinafter FDA Off-Label Guidance].
86

U.S. Food and Drug Admin., Public Hearing on Promotion of FDA-Regulated Medical Products
Using the Internet and Social Media Tools (Nov. 12–13, 2009), http://www.fda.gov/AboutFDA/
CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm184250.htm [hereinafter 2009
FDA Internet and Social Media Hearing].
87

John Sullivan, et al., The FDA and the Regulation of Social Media, Corporate Counsel (Jun.
27, 2012), available at http://www.dechert.com/files/Publication/ef3f4a16-9d0a-4178-b84c-
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“will hold companies responsible for their direct actions” and may also hold companies
“responsible for third-party postings . . . if the company explicitly encouraged that
third-party to post improper information” and even if the company did not request that
content.88 For example, if a user discusses off-label uses of a drug in a video posted on
the internet, even though the company did not request off-label videos, the FDA may
consider such videos solicited.89
Despite the FDA’s recognition that the internet and social media have fundamentally
changed the way that companies communicate with the public, the FDA recommended
that any substantive responses from companies to unsolicited requests for information
regarding off-label use of drugs not occur through the internet or interactive promotional
media due to the inherently public and permanent nature of these communications.90
Ultimately, industry expressed concern about the draft guidance issued by the FDA,
maintaining that it “will unnecessarily stifle the flow of accurate scientific information
that has otherwise been intended both by the industry and FDA, as well as handicap
the unique benefits of social media that FDA should embrace in order to further public
health.”91 As a result, most drug and device companies have remained risk averse when
it comes to using social media or the internet for DTC advertisements and are far behind
in their implementation and use of social media.92 Ironically, the FDA has become
increasingly skilled with using social media tools on its own behalf.93 The FDA’s failure
to articulate clear internet and social media guidelines and its use of regulatory letters
and enforcement actions to hold companies accountable has generated additional
uncertainty within the industry.
iii. FTC “.com” Guidance and Current Use of Social Media
The FTC recently released guidance on “.com Disclosures,”94 which could have several
implications for products regulated by the FDA, if the FDA decides to follow the FTC’s
approach. For example, the FTC guidance recommends that disclosures which are an
“integral part of a claim or inseparable from it should not be communicated through a
hyperlink.”95 Specifically, the FTC states that hyperlinks, even one labeled “Important
Health Information,”96 “should not be used . . . [for] important health and safety
ac2ee9197917/Presentation/PublicationAttachment/c775d639-aa34-4047-97c4-b27872755ac2/
FDA%20Dechert.pdf.
88

Id.

89

FDA Off-Label Guidance, supra note 85, at 5.

90

Id. at 10.

91

Jamie Kendall & Noah Mallon, Does FDA’s Draft Guidance on Responding to Unsolicited OffLabel Requests Align With FDA’s Mission to Promote the Public Health?, 2-3 FDLI, Food and Drug
Policy Forum (Mar. 14, 2012).
92

Digital Budget for Pharma Expected to be 20% for 2013, supra note 9.

93

FDA’s Social Media Assets – Twitter Overview, EyeonFDA (June 23, 2011), http://www.
eyeonfda.com/eye_on_fda/2011/06/fdas-social-media-assets-twitter-overview.html.
94

Federal Trade Commission, .com Disclosures: How to Make Effective Disclosures in Digital
Advertising, 10 (Mar. 2013), http://www.ftc.gov/os/2013/03/130312dotcomdisclosures.pdf
[hereinafter FTC Online Guidance].
95
96

Id.
Id. at 10 (example 4).
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information” because “required disclosures about serious health and safety issues are
unlikely to be effective when accessible only through a hyperlink.”97 The FTC, however,
provides no evidence as to why such health information hyperlinks are unlikely to be
effective. Nevertheless, the FTC maintains that “integral” or “inseparable” disclosures
“should be placed on the same page and immediately next to the claim, and be
sufficiently prominent so that the claim and the disclosure are read at the same time.”98
The FTC also reiterates that “any disclosure that is integral to the primary claim should
be immediately adjacent to that claim.”99
The FTC recognized that when disclosure in a space-constrained advertisement is not
possible, “it may, under some circumstances, be acceptable to make the disclosure
clearly and conspicuously on the page to which the advertisement links.”100 When using
a hyperlink to lead to a disclosure, the FTC recommends: (1) making the link obvious;
(2) labeling the hyperlink appropriately to convey the importance, nature, and relevance
of the information that it leads to;101 (3) using consistent hyperlink styles; (4) placing
the hyperlink as close as possible to the relevant information it qualifies and make it
noticeable; (5) taking consumers directly to the disclosure on the click-through page;
and (6) assessing the effectiveness of the hyperlink by monitoring click-through rates.102
The FTC also recommended designing advertisements so that “scrolling” “is not
necessary in order to find a disclosure”; however, if scrolling is necessary, the FTC
recommended using text or visual cues to encourage consumers to scroll to view the
disclosure.103 Moreover, the FTC indicated that companies should consider how linking
or “mouse-overs” may work on computers but may not work mobile devices.104 The
guidance explains that if an advertisement without a disclosure would be deceptive,
unfair, or violate one of the FTC rules, and “if a particular platform does not provide an
opportunity to make clear and conspicuous disclosures, then that platform should not
be used to disseminate advertisements that require disclosures”105 Although not directly
applicable to products regulated by the FDA, the FDA may use the FTC’s guidance as it
begins drafting additional guidance regarding DTC advertisements in online media and
social media platforms in 2014.

97

Id. at 10, A6.

98

Id. at 10.

99

Id. at A6 (example 4).

100

Id. at ii.

101

Id. at 11–12 (noting that hyperlinks that say “‘disclaimer,’ ‘more information,’ ‘details,’
‘terms and conditions,’ or ‘fine print’ do not convey the importance, nature, and relevance of the
information to which they lead and are likely to be inadequate.” The FTC added that labels such as
“important information” or limitations may also be inadequate. While the FTC said there is “no onesize-fits-all” word or phrase to use in a hyperlink label, “more specificity” is better).
102

Id. at ii (emphasis added).

103

Id. For example, “see below for important information”; but not “details below” because it
provides “no indication about the subject matter or importance of the information that consumers
will find and are not adequate cues.” Id. at 9.
104

Id. at 12.

105

Id. at iii.
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IV. FDA OVERSIGHT AND ENFORCEMENT OF DTC ADVERTISING
The FDA’s Office of Prescription Drug Promotion (OPDP)106 regulates drug advertising
and promotion. OPDP has four DTC review groups that review final DTC materials,
provide advisory comments on draft materials that companies submit voluntarily,
and review materials cited in complaints submitted by competitors or consumers.107
Because the FDA regulations require that companies submit final DTC promotional
materials to the FDA at the time of their initial dissemination to the public108 (often
referred to as “postmarketing submission” requirements), the OPDP review groups
monitor television, magazines, and manufacturer websites to ensure compliance.
OPDP also monitors DTC advertisement to ensure that advertisements are not false or
misleading;109 that advertisements have adequate contextual and risk information; and
that advertisements are presented in understandable language to fulfill the fair balance
requirement.110 Additionally, OPDP monitors DTC advertisements through a routine
surveillance and monitoring program, including the “Bad Ad” Program.111
If OPDP finds a DTC advertisement or promotional piece that violates the law
or guidelines issued by the FDA, it issues a regulatory letter to the manufacturer
disseminating the violative material.112 There are two types of letters that OPDP
issues: a Notice of Violation (NOV) Letter (or “untitled letter”) for minor violations,
and a Warning Letter for more serious violations.113 Other enforcement actions include
product seizures, criminal actions, injunctions, and consent decrees.114 The FDA may
also hold any person who disseminates a false or misleading drug DTC advertisement
liable for civil monetary penalties.115 Despite having these enforcement tools, OPDP
has previously faced difficulty prioritizing and taking enforcement actions against

106

This office was previously DDMAC, and before that had several other names. Pines, supra note
52, at 495–96.
107

Prescription Drugs: Trends in FDA’s Oversight of Direct-to-Consumer Advertising, Testimony
Before the Subcomm. on Oversight and Investigations, Comm. on Energy & Commerce, U.S. Gov’t
Accountability Office, GAO-08-758T, 5 (May 8, 2008) (statement of Marcia Cross, Director, Health
Care) [hereinafter GAO-08-758T].
108

21 C.F.R. § 314.81(b)(3)(i) (2013). This is to be transmitted on an FDA Form 2253.

109

U.S. Food and Drug Admin., From the manufacturers’ mouth to your ears: Direct to consumer
advertising (June 6, 2013), http://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm319379.
htm. Drug promotion is considered false or misleading if it: (1) promotes the drug as being more
effective than actually demonstrated; (2) implies that a drug is safer or has fewer or less severe side
effects than demonstrated; (3) claims, without substantial evidence, that its product is better than a
competitor’s drug; (4) gives a false, misleading or unbalanced presentation of risk information; and
(5) promotes the product as being able to treat conditions not approved by FDA. Id.
110

FDA Risk Information Guidance, supra note 79, at 4.

111

U.S. Food and Drug Admin., Truthful Prescription Drug Advertising and Promotion (Nov.
26, 2013), http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/
DrugMarketingAdvertisingandCommunications/ucm209384.htm.
112

GAO-08-758T, supra note 107, at 1–2.

113

Id. at 6. FDA may require a “correction advertisement” for serious violations. Id.

114

Id. at 6, note 8.

115

FDA 2009 Rept. to Congress, supra note 78, at 4.
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submitted promotional materials that may be violative due to the increasing number of
materials submitted.116
Although the FDA established criteria to prioritize review of DTC advertisements in
2008, the criteria still do not ensure that OPDP systematically screens the DTC materials
it receives against the established criteria to identify those advertisements that are the
highest priority for review.117 Further, a policy change requiring the FDA’s Office of
Chief Counsel (OCC) to review all draft regulatory letters (e.g., NOVs and Warning
Letters) that took place in 2002 led to the FDA issuing about half as many letters as
it had previously.118 Moreover, while companies complied with the FDA requests to
remove materials that were still being disseminated and issuing corrective materials,
these actions generally did not occur until five to twelve months after the FDA’s
regulatory letter was sent.119 As a result, some products remained on the market, on
average for about seven months, despite their violative nature.120 In addition, regulatory
letters did not always prevent drug companies from later disseminating similar violative
materials for the same drugs.121
OPDP began to refocus its attention on DTC advertising on the internet in 2010,
when it issued thirteen regulatory letters related to online media including “emails,
websites, website videos, social media, and/or webcasts.”122 In 2011, the FDA issued
seven warning letters related to misleading online promotion, most involving “the
placement and/or lack of prominence of risk information.”123 Some commentators
have attributed the decrease in internet-promotion related Warning Letters issued by
the FDA to companies relying more on help-seeking and reminder type sponsored links
in order to avoid the brief summary requirement.124 In 2012, OPDP issued twenty-five
untitled letters and three Warning Letters for promotional violations, bringing its total
to 173 regulatory action letters regarding communications about FDA regulated drugs
or devices between 2008 and 2012.125 Overall, between 2008 and 2012, the FDA found

116

In 2008, DDMAC received 10,861 Internet DTC materials. See id. at 6.

117

GAO-08-758T, supra note 107, at 8–9.

118

Id. at 3–4, 11. As a result, letters were issued on average 8 months after violative materials
were first disseminated; when “companies had already discontinued more than half of the violative”
advertisements.
119

Id. at 12.

120

Id.
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Id. at 5. For example, of the 89 drugs for which FDA cited violative DTC materials from 1997
through 2005, 25 drugs had DTC materials cited in more than one regulatory letter, sometimes for
similar types of violations.
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Kassity Liu, FDA and Social Media: The Impact of Social Media on Prescription Drug
Advertising, Jolt Digest (Apr. 17, 2012), http://jolt.law.harvard.edu/digest/digest-note/fda-andsocial-media-the-impact-of-social-media-on-prescription-drug-advertisin.
123

Jacqueline West, National Marketing Gone Unintentionally Global: Direct-to-Consumer
Advertising of Pharmaceutical Products and the Internet, 11 J. Int’l Bus. & L. 405, 414–15 (2012).
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Id. at 415 (citing 2009 FDA Internet and Social Media Hearing, supra note 86, at 438–40).
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Mark Senak, FDA Communications: Oversight in a Digital Era, 2008-2013, eyeonFDA (Apr.
2013), http://www.eyeonfda.com/wp-content/uploads/2013/03/FDA-Communications-Oversight-ina-Digital-Era1.pdf.
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“290 digital violations.”126 Of these violations, over half were for companies that failed
to include risk information or minimized the risk, while eighteen percent overstated
efficacy.127 However, of the 173 regulatory action letters, “less than 1 percent involved
a social media platform as the basis for the letter.”128
Nevertheless, the lack of transparency in the FDA’s enforcement discretion, coupled with
the FDA’s vague guidance is problematic for several reasons. First, these new avenues of
communication create ways for companies to reach millions of patients who may need
treatments or are avoiding seeing a doctor. As a result, patients may not be receiving
information that could change their health and lives. Second, the lack of guidance and
transparency raises First Amendment issues because advertisements are a form of
commercial speech.129 Third, the current regulatory regime hurts physician training and
education because doctors may also be motivated to learn about new drugs through
DTC advertisements they see directly or through conversation with their patients.130
Despite these negative effects, the FDA has been unable to tackle the challenges of DTC
promotion online.

V. THE DIFFICULTIES POSED BY SOCIAL MEDIA AND INTERNET
DTC ADVERTISEMENTS
The use of DTC advertisements in social media and on the internet creates several
challenges for companies. First, providing fair balance is difficult because Twitter,
sponsored links, and share widgets generally do not have enough space for the FDA
required risk disclosures. For static websites, companies had been using an industrycreated practice known as the “one-click-away” rule, which assumes that it is sufficient
to present some information about a drug, absent risk disclosure, so long as information
regarding the risk is only “one-click away.”131 However, “the mere possibility of access
to risk information does not necessarily translate into a realistic presentation of risks.”132
Drug and device companies widely used “one-click away” until April 2009, when the
FDA issued fourteen (NOV) letters to manufacturers who sponsored search-engine
advertisements on Google for drugs.133
126

Mark Senak, Comparing Types of Violations Between Digital and Non-Digital, eyeonFDA (Apr.
11, 2013), http://www.eyeonfda.com/eye_on_fda/2013/04/comparing-types-of-violations-betweendigital-and-non-digital.html. This represented only 43% of the total violations. Id.
127

Id. (finding 56% of digital violations failed to include risk information or involved minimization
of risks).
128

Senak, supra note 125.

129

See e.g., Thompson v. Western States Med. Ctr., 122 S.Ct. 1497 (2002) (striking down a
provision in the FDA Modernization Act (FDAMA) that prohibited pharmacies from advertising
compounded products); Virginia Board of Pharmacy v. Citizens Consumer Council, Inc., 425 U.S.
748 (1976) (invalidating a ban on drug price advertising).
130

See Patient Ed: How Patients Learn in the Digital Age, supra note 6.

131

Doug Flora, The FDA and Social Media: A Primer, The Fosbury Flop (Sept. 27, 2010), https://
reputationcommunications.wordpress.com/2010/09/27/the-fda-and-social-media-a-primer/.
132

Jeremy A. Greene & Aaron S. Kesselheim, Pharmaceutical Marketing and the New Social
Media, 363 New Eng. J. Med. 2087, 2088 (2011).
133

Stephanie Clifford, FDA Rules on Drug Ads Show Confusion as Applied to Web, NYTimes.com,
Apr. 16, 2006, http://www.nytimes.com/2009/04/17/business/media/17adco.html?_r=0.

20

Health Law & Policy Brief • Volume 8, Issue 2 • Spring 2014

The NOV letters asserted that information in a sponsored link that includes a website
address consisting of the trade name for a drug, and that appears on the results page
of an internet search engine when a keyword search is conducted, is not a reminder
advertisement but instead is “labeling” and “advertising.”134 As a result, OPDP asserted
that all of the mandatory risk information “must likewise appear on the face of the
sponsored link and will not be considered in the disclosure analysis even if fully . . .
available one-click away.”135 The FDA stated that its promotional laws “are the same
regardless of the medium.”136 Thus, the FDA found the sponsored link misleading
because it suggested efficacy without disclosing risk information.137 The FDA also
found a sponsored link misleading, even though it made “no explicit claim about the
drug.”138 These actions illustrate how the FDA may find an “implied connection and
require risk disclosures in the link text,” even if the sponsored link or widget does not
explicitly state that the product treats the disease.139
In 2010, the FDA also sent its first untitled letter regarding information generated by
the “Facebook Share” widget on one of Novartis’s websites. Clicking on the widget sent
Novartis-authored information about the leukemia drug Tasigna to a user’s Facebook
page. The FDA stated that the “shared content [wa]s misleading because it ma[de]
representations about the efficacy of Tasigna but fail[ed] to communicate any risk
information associated with the use of this drug.”140 In order for promotional materials
to be truthful and non-misleading, “they must contain risk information in each part
as necessary to qualify any claims made about the drug.”141 As a result, the FDA
may determine that placing risk disclosures “one-click away” is sufficient if the text
of the sponsored link discusses only the disease, does not name the product, makes
no implied or express product claims, and the product is instead first named, along
with risk disclosures, on the other side of the link.142 Until the FDA issues further
guidance, however, the requirements in this area remain uncertain. While the FDA

134

Thomas Sullivan, FDA: Examination of Online DTC Promotion, Pol’y & Medicine (Jun.
1, 2011), http://www.policymed.com/2011/06/fda-examination-of-online-direct-to-consumerprescription-drug-promotion-notice-for-comment.html.
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Id. The FDA was especially concerned because one drug had a boxed warning, and another a
bolded warning.
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Clifford, supra note 133 (risk information “was required despite the length limitation of Internet
search ads”).
137

U.S. Food and Drug Admin., Letter from Sangeeta Vaswani, DDMAC, to Christopher
Graham, sanofi-aventis U.S. LLC., FDA.gov (Mar. 26, 2009), http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/
WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM166248.pdf.
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Sullivan, supra note 87.
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Id. (noting that the FDA has issued over a dozen such untitled letters on sponsored links or share
widgets).
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U.S. Food and Drug Admin., Letter from Karen R. Rulli, DDMAC, to Lisa Drucker,
Novartis Pharmaceuticals Corp, FDA.gov. (Aug. 4, 2010), http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/
WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM221325.pdf.
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could potentially adopt an approach similar to the use of “major statements” adopted
by the FTC for broadcast advertisements, “possibly via a link to another web page,”
this may be “unworkable, since the text of a ‘major statement’ may be too lengthy . . .
for the space limitations of Internet links and widgets.”143 Accordingly, a link to safety
information is not likely to suffice.
An approach that is “more consistent” with the FDA’s guidance is to present safety
information on the vertical display of a webpage, which may allow an individual to
“utilize scrolling in order to view the complete information.”144 If this approach is
utilized, risk information should be visible when the user first opens the webpage. The
FDA’s guidance also addresses the use of headers and signaling.145 Thus, companies
should use “signals such as ‘continued,’ ‘more’ and ‘select,’” if safety information
continues from page-to-page, which is likely “given the smaller footprint and displays”
available in social and mobile platforms.146
Unlike television, social media is unique because consumers have the opportunity to
respond to online promotional material and communicate their opinions with others.
This capability, however, presents risks for drug companies because dissatisfied patients
can post harmful information that may discourage others from taking the medication and
may even discourage online viewers from seeing a doctor, which may have public health
implications. There is also concern that companies may be influencing or controlling
content on web-based social media by supporting “third-party bloggers, posters, and
Twitter users who make flattering claims and discredit negative claims about their
products in online discussions.”147 Moreover, it may no longer be technically possible
for companies to distinguish a manufacturer website from a manufacturer initiated chat
room or comment area because applications such as Google’s “Sidewiki” can “layer a
social network of commentary onto any existing static Web site, with or without the site
owner’s consent.”148
Without further guidance from the FDA, the difficulties posed by interactive promotional
media will continue. For example, in December 2012, the FDA sent a Warning Letter to
AMARC Enterprises regarding its cancer supplement (non-FDA approved) Poly MVA.
The letter–the first of its kind–cited a March 10, 2011 post on AMRAC’s Poly MVA
Facebook page, in which a consumer noted how the product had “done wonders for
me.”149 FDA took issue with the fact that AMRAC “liked” this favorable consumer
143

Id.
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Sara Stults, It Doesn’t Have to Hurt: A Social Media Primer, FDLI Update Magazine (Sept.Oct. 2011).
145

Id.
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Greene & Kesselheim, supra note 132.
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West, supra note 123 (explaining the application left no control over the content of the Sidewiki
to the site owner).
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U.S. Food and Drug Admin., Warning Letter to Mr. Albert Sanchez, CEO, AMARC Enterprises,
Inc., FDA.gov (Dec. 11, 2012), http://www.fda.gov/iceci/enforcementactions/warningletters/2012/
ucm340266.htm which states: “We also note claims made on your Facebook account.” “The
following are examples of the claims: In a March 10, 2011 post which was “liked” by “Poly
Mva”: “PolyMVA has done wonders for me. I take it intravenously 2x a week and it has helped me
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testimonial, however, FDA did not “restrict consumers from ‘liking’ a drug or device
company’s Facebook page or posts.”150 Nevertheless, it is unclear whether “liking” is
akin to “favoriting” a Twitter user, “retweeting” a post, “sharing” or “re-posting” content
from other uses, or “+1” a post on Google+.151 Waiting for further guidance from the
FDA, however, is not an option for drug or device companies because consumers have
used these platforms for years to discuss products, and the industry’s absence from this
conversation is counterproductive.
Research suggests that DTC advertising has a number of benefits for patients and
consumers. For example, a recent study found that DTC advertisement for aromatase
inhibitors “was associated with increases in appropriate prescriptions with no significant
effect on inappropriate prescriptions.”152 Another study showed “no strong indication
that either consumer- or provider- directed promotion substantially raised retail-level
prices.”153 In fact, while some physicians believe that DTC advertisements misinform
patients, overemphasize drug benefits, encourage drug overutilization, and ultimately
increase the cost of healthcare,154 such beliefs fail to recognize that over seventyfive percent of the prescription drugs patients receive are generic.155 Moreover, even
if patients ask for a branded drug, insurers often mandate the generic and most state
laws require generics unless a physician indicates the brand-name drug is medically
necessary.156 In addition, a recent survey of physicians showed that almost fifty percent
agreed that DTC advertisements inform, educate, and empower patients; sixty-eight
percent agreed that DTC advertisements encourage patients to contact a physician;
sixty-four percent agreed that DTC advertisements promote patient dialogue with
healthcare providers; and over fifty percent agreed that DTC advertisements removed
tremendously. It enabled me to keep cancer at bay without the use of chemo and radiation…Thank
you AMARC.”
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stigma associated with certain diseases.157 These findings should encourage industry to
increase its presence and investment in interactive promotional media.158
In fact, pharmaceutical companies have approximately 200 Twitter feeds, over 150
sponsored or funded YouTube channels, and over 100 Facebook pages,159 several of
which are very successful. The explosion of social media use by pharmaceutical
companies has led to some companies creating guidelines for their employees governing
what can and cannot be posted online. For example, in 2010, Roche distributed a
guidance letter to employees that outlined personal and professional principles for
online activities when speaking about Roche.160 Similarly, AstraZeneca published a
white paper that “outlin[es] its guidelines for social media use”161 and hosted a Twitter
chat to raise awareness about its patient prescription program.162 Manufacturers
can also utilize social media to control their image; Eli Lilly has an online presence
with a blog, Facebook page, and a Twitter feed, which focus on public policies about
pharmaceuticals, as well as a YouTube page that features videos about Eli Lilly’s
research and philanthropic work.163
In 2011, Pfizer Canada posted a flow chart online that instructs companies on how
to respond to social media communications.164 Johnson & Johnson has created an
active social presence that utilizes a blog that is supplemented with YouTube and
Facebook pages.165 Manufacturers have also utilized social media for more specific,
targeted campaigns that focus on particular illnesses and treatments. For example,
157
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Boehringer Ingelheim started the “Drive4COPD,” a campaign that calls on consumers
to get screened for chronic obstructive pulmonary disease (COPD), and uses Twitter,
Facebook, YouTube, and Flickr to promote the campaign.166 Similarly, Novo Nordisk
has a Twitter feed, “Race with Insulin,” which features IndyCar racer Charlie Kimball,
who discusses his experience with diabetes.167 In addition, UCB, Inc. collaborated
with PatientsLikeMe to establish a free online community for people with epilepsy.168
More recently, Janssen posted what appears to be a branded Facebook advertisement
for Axert, a migraine treatment.169 Finally, Sanofi launched Facebook and Twitter pages
for diabetes.170 On the company’s Facebook page, any clinical questions are directed
to a separate tab and often answered privately; on the company’s Twitter page, medical
concerns are addressed via direct message.171
While these examples demonstrate promise, manufacturers that decide to use such
social media platforms should use caution until the FDA produces more specific
guidance regarding the use of interactive promotional media. Such guidance is
particularly important given that the FDA recently issued an Untitled Letter notifying
Institute Biochimique SA (IBSA) that it’s Facebook page for Tirosint was “false and
misleading because it ma[de] representations about the efficacy of Tirosint, but fail[ed]
to communicate any risk information associated with its use and it omit[ted] material
facts.”172 FDA was particularly concerned because Tirosint is associated with a number
of serious risks and includes a Boxed Warning, and by failing to “communicate any
of the risks associated with its use,” the “Facebook webpage misleading suggests that
Tirosint is safer than has been demonstrated.”173
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VI. RECOMMENDATIONS: WHAT CAN WE LEARN FROM FDA’S
“FIRST” SOCIAL MEDIA GUIDANCE?
Answering the calls from industry, patients, and Congress, the FDA issued its “first” draft
social media guidance in January 2014, entitled “Draft Guidance for Industry: Fulfilling
Regulatory Requirements for Postmarketing Submissions of Interactive Promotional
Media for Prescription Human and Animal Drugs and Biologics” (“Guidance”).174
The Guidance document acknowledges the “unique technological features” and
“novel presentation and content features” of “interactive promotional media,” which
FDA defines to include “modern tools and technologies that often allow for real-time
communications and interactions (e.g., blogs, microblogs, social networking sites,
online communities, and live podcasts) that firms use to promote their drugs.”175 The
Guidance: (1) “describes FDA’s current thinking on what the Agency considers to be
interactive promotional media”; (2) “outlines the considerations taken into account in
determining if product communications using interactive technologies are subject to
the FDA’s postmarketing submission requirements”; and (3) makes “recommendations
for how companies can fulfill the regulatory requirement to submit postmarketing
promotional materials to the FDA in a practical manner to address the potential
volume of real-time information that is continuously posted and shared through various
interactive promotional media platforms.”176
Specifically, the Guidance states that companies are responsible for submitting
post-marketing information if they “own, control, create, influence, or operate” the
interactive promotional media platform.177 The FDA emphasizes that a manufacturer
is responsible for promotion both on websites that it owns or controls and third-party
websites, if the manufacturer or firm “exerts influence over a site in any particular, even
if the influence is limited in scope,” such as “collaborat[ing] on or ha[ving] editorial,
preview, or review privilege over the content provided.”178 Manufacturers are generally
“not responsible for [user generated content (UCG)] that is truly independent of the firm
(i.e., is not produced by, or on behalf of, or prompted by the firm in any particular),”
such as content posted on social media sites by third-parties or individual users.179
174
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and Animal Drugs and Biologics, FDA.gov (Jan. 2014), www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/UCM381352.pdf [hereinafter FDA PostMarketing Interactive Promotional Media Guidance].
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The FDA also explained that manufacturers are responsible for content generated
by an employee or agent who is acting on behalf of the manufacturer to promote the
manufacturer’s product.180 The remainder of the Guidance explains the frequency with
which firms must submit promotional materials generated on interactive promotional
media platforms.181
While the Guidance focuses on post-market submission requirements, the FDA’s general
approach to interactive promotional media may be instructive to industry and stakeholders
that are trying to address concerns such as: (1) the reporting of adverse events; (2)
the use of links; (3) required financial or employee disclosures (e.g., transparency);
(4) the ability to comment or correct independent third-party misinformation about
drugs or devices; and (5) the presentation of risk and benefit information in light of the
space limitations and visual appearance of interactive promotional media platforms.
Given that the FDA has already announced plans to publish three additional guidance
documents on interactive promotional media this year, there are several factors that
FDA and industry should consider.182
A. The Use of Links & Risk Information
The FDA should formally permit companies to use the “one-click away” rule. The “oneclick away” rule is consistent with FDA’s approach to DTC television advertisements,
which direct viewers to look for full prescribing and risk information either on the
internet or in a print advertisement due to the lack of time and/or space in the television
advertisement. Adopting this rule would satisfy concerns previously expressed by the
FDA because the nature and use of hyperlinks on the internet makes it more likely that
consumers would click on the hyperlink enabling them to view the risk information. In
drafting this guidance, the FDA should consider the FTC’s recently released guidance
on “.com Disclosures.” For example, the FDA should consider allowing the use of
hyperlinks when disclosure in a space-constrained advertisement is not possible.
Under these circumstances, the FDA could recommend (consistent with the FTC’s
guidance): (1) making the link obvious; (2) labeling the hyperlink appropriately to
convey the importance, nature, and relevance of the information it leads to; (3) using
consistent hyperlink styles; (4) placing the hyperlink as close as possible to the relevant
information it qualifies and making it noticeable; (5) taking consumers directly to the
disclosure on the click-through page; and (6) assessing the effectiveness of the hyperlink
content provider” as someone “responsible, in whole or in part, for the creation or development of
information provided through the Internet or any other interactive computer service.” 47 U.S.C.
§ 230(f)(3) (2012).
180
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by monitoring click-through rates.183 The FDA could also monitor websites and social
media to ensure that risk information truly was only one-click away and that a hyperlink
actually takes consumers to a website or information that the FDA has actually reviewed
and approved (e.g., labeling or PI).184
The FDA’s guidance should also address the use of “rollover and scrolling functions” that
can “enable direct connections to safety and efficacy information,” when using social
media tools with limited space.185 The FDA could recommend that advertisements,
which require “scrolling” to find required risk disclosure information, include text
or visual cues to encourage consumers to scroll to view the disclosed information.186
Moreover, the FDA could allow companies to use “mouse-overs” on computers to
display required disclosures such as risk information, as long as the “mouse-overs”
otherwise complied with the FDA’s guidance on displaying risk information. Conversely,
manufacturers may want to avoid scrolling or “mouse-overs” on mobile devices since
use of such mechanisms on these platforms may prevent fair and balanced presentations
of information. Manufacturers should also consider working with mobile medical
application developers to address these issues early in the design and testing process
to prevent any unnecessary updates or modifications once the application has launched,
which may be costly or interrupt user functionality. For example, mobile applications
that display promotional advertisements could be designed to prominently display links
to risk information on all necessary screens.
Manufacturers should also consider factors unique to different platforms. For example,
Twitter can inform many people quickly about drug approvals or the release of new
data at a scientific meeting. Companies may also use unbranded tweets to allow linking
to other branded sites. Tweets about drugs that do not carry a boxed warning, may
use a BRAND (generic) name and “include other links directly to the brand site or
other information mentioned in the Tweet;” the FDA may treat such tweets as reminder
advertisements. 187 When the tweet is used to communicate about a drug with a “boxed
warning, the tweet should include a URL that navigates directly to display the full PI;
. . . format of the URL to the PI is important.”188 This page that is navigated to by the
URL can contain “other fixed links to the brand website or other related information.”189
The use of claims in a tweet, however, is “problematic because the safety information
cannot display completely with the 140-character limit.”190 Because the FDA does not
consider linking to such information sufficient, the FDA regulations require that all
risk information appear on the face of the sponsored link. One option that companies
may pursue is “Deck.ly,” a new technology that allows for the creation of tweets that
183
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are much longer than 140 character posts that were traditionally allowed on Twitter.191
Interestingly, OPDP Director, Tom Abrams said that companies should be able to
promote their drugs “using a space limited venue, such as 140 characters.”192
Because FDA also regulates pre-approval promotion, tweets describing new data, either
for a marketed drug’s investigational use or for an investigational drug, “should not state
any specific investigational uses or potential indications or include any claims of safety
or efficacy.”193 Manufactures may “‘disseminate[e] . . . scientific findings in scientific or
lay media’ without engaging in promotional activity, but promotional claims of safety or
effectiveness for a use for which the product is under investigation are subject to FDA
regulation as advertising or labeling.”194 When not using the product name for the drug,
the tweet may include the manufacturer name, data presented, and the study phase.195
The use of social bookmarking and sharing widgets pose different challenges
for companies. When the “share” button is selected, a display of the widgets for
bookmarking or sharing is provided for the user to select from and there is an option
for email. Once a user selects share, content is passed from the original website and
posted on a social sharing site. If a user posts branded promotional content without
any modification, the content reflects what was reviewed and approved on the original
website, thus attaching the manufacturer to the message.196 Users, however, can edit
content and post the content on a social sharing site. As a result, companies should
consider establishing separation between what is manufacturer sponsored and what is
not. If the manufacturer “does not create, control, maintain or participate in content on
the social sharing site or someone’s social media page,”197 the FDA may consider there
to be enough separation. Thus, companies may benefit from deciding whether users can
edit material, and if so, opt to permit posting of edits only after the manufacturer has
reviewed the edited content.
Manufacturers should also consider paying close attention to comments added to
company sponsored or supported websites by individual users of those sites due to
the various differences from site-to-site. For example, “YouTube allows disabling the
commenting feature, so a company can post a video without allowing comments” and
Google added a “Safe Watch” feature, which allows channel owners with ten or more
videos to control what videos show up on the watch pages of YouTube.198 It is also
possible to “disable video embedding to limit the use of company videos outside of
191
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the company’s more controlled YouTube environments.”199 Google recently created
the YouTube One Channel to give users a more friendly and flexible template.200
The channel still allows companies to “turn off comments, and their content, while
shareable, could be set to play only on YouTube” to prevent a video from playing on
someone’s Facebook feed “where companies could not necessarily monitor or respond
to comments, but might be held to adverse events reporting requirements.”201
Facebook’s official policy indicates that it will no longer grant companies the ability to
disable comments on wall posts, photos, and videos, unless the company’s Facebook
page is a branded page “solely dedicated to a prescription drug;” companies, however,
are still able to control the creation of original content or posts.202 In response to these
changes, some companies shut down their Facebook pages.203 Other companies screen
for and remove improper comments, but this creates additional responsibilities and
costs associated with training personnel to screen for and remove such comments.204
Companies should consider disclosing policies or “terms of use” that govern their
interactive social media platforms, specifically accounting for the nuances and
differences noted above, which some companies are already doing.205 Such policies
should be clear as to what UGC can consist of, which type of topics and language are
permissible and prohibited (e.g., off-label uses), and how the manufacturer will prescreen and remove content. Such policies may assist manufacturers in addressing thirdparty misinformation, as discussed below.
B. Correcting Independent-Third Party Misinformation
The FDA should consider allowing companies to have broad latitude in taking a
proactive approach—wholly at their discretion—to correcting misinformation about
their products that appears in interactive promotional media, including with respect
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to third-party interactive media that they do not control or influence.206 The FDA’s
revised and future guidance, therefore, should include recommendations for industry
and stakeholders on how to correct such misinformation in a compliant manner, with
realistic requirements for disclosures and balance appropriate for the space and other
limitations of such media. In such guidance, FDA should also explain acceptable ways,
using examples,207 that manufacturers can correct misinformation without triggering
full requirements applicable to promotional materials (e.g., postmark submission). For
example, an exemption from promotional labeling requirements could be established
if: (1) language used to correct third-party misinformation remains consistent with the
product’s PI; (2) addresses the specific misinformation only; (3) provides a link to the
approved labeling, if possible; and (4) is reviewed by an appropriate internal compliance
process before posting. FDA could request additional information if necessary
and monitor corrective statements through general surveillance or recordkeeping
requirements. Alternatively, FDA could ask companies to certify annually that they are
correcting third-party misinformation in compliance with FDA’s future guidance.
C. Transparency & Disclosure
Manufacturers that post promotional content or corrective information on interactive
promotional media should be transparent and make full disclosure about the relationship
of the author to the manufacturer, to promote trust with consumers and reduce confusion
about the source of the information. Transparency is critical for establishing an online
community where members feel comfortable sharing information and learning from
each other.208 Consistent with the FDA’s first Guidance, manufacturers should clearly
identify UGC and communications of its employees or third-parties acting on behalf of
the manufacturer. The FDA stated that such disclosure could be achieved by including
a manufacturer’s identifier (e.g., name or logo) as part of the communication. However,
in future guidance, the FDA should provide greater clarity and/or additional examples
regarding the identification issue. For instance, on Facebook, Twitter, LinkedIn, or other
social media platforms, users have profiles that may indicate their place of employment
(e.g., “Social Media Manager, Company XYZ”). Thus, the FDA should clarify whether
communications in these platforms require any further disclosure. Similarly, in blogs,
chat rooms, or other forums where users may not have profiles or are anonymous, the
FDA should clarify whether the use of a disclaimer (e.g., “I am an employee at Company
X …”) in posts is sufficient. The FDA should also clarify how prominent disclosures
206
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should be (e.g., larger text, bold, at the beginning of the content, etc.) and where they
should be place within an interactive platform. Disclosure is important not only to
promote trust with consumers, but also to minimize the appearance of impropriety or
creation of misleading impressions.
Transparency and disclosure are also important on interactive promotional media
because the FDA clarified in its first Interactive Promotional Media Guidance that the
FDA regulates product promotion “conducted on [a] firm’s behalf,” and that companies
are responsible for UGC and communications of its employees, agents, or anyone “who
is acting on behalf of the firm to promote the firm’s product.”209 The FDA explained
that a manufacturer is responsible for content such as “comments on a third-party site
about the firm’s product” that were written by a manufacturer’s “medical science liaison
or paid speaker (e.g., a key opinion leader) acting on the firm’s behalf.”210 Likewise,
the FDA explained that a manufacturer is responsible for the content on a blogger’s
site “if the blogger is acting on behalf of the firm.”211 Thus, to the extent manufacturers
allow employees, consultants, or agents to create corrective statements or UGC on the
manufacturer’s behalf, they should require such individuals to disclosure the relationship
of the author to the manufacturer.
Manufacturers and/or their corporate executives may also implicate the FDA promotional
regulations by using interactive promotional media. For example, the FDA recently
sent a Warning Letter to Aegerion Pharmaceuticals, Inc., based on comments their
chief executive officer (CEO) had made on the CNBC television show “Fast Money”
suggesting that Aegerion’s drug, Juxtapid could be used effectively for unapproved
indications.212 Prior to this instance, the former CEO of InterMune was investigated and
convicted of wire fraud for the creation and dissemination of a press release that contained
false and misleading information about the efficacy of Actimmune.213 Corporate
executive use of interactive promotional media could also implicate Regulation Fair
Disclosure (RegFD), which requires “that whenever a company, or a person acting on its
behalf, discloses material, nonpublic information to analysts, investment professionals
or company stockholders, the company must make that information simultaneously
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available through broadly disseminated public disclosure.”214 Consequently, the
Securities and Exchange Commission (SEC) could bring an enforcement action against
a manufacturer or its executive who uses interactive promotional media to communicate
about the success or failure of certain drugs or devices already on the market or in FDA
approved clinical trials. Because such information is likely material, the manufacturer
could face action unless investors and the markets “have been alerted as to which
specific social media outlets would be used to disseminate such key information.”215
As a result, manufacturers should consider updating internal policies, procedures, and
training as necessary to outline the requirements that employees (including executives),
consultants, or agents must follow if permitted to use interactive promotional media.
Manufacturers may also need to address whether licensed physicians who engage as paid
contributors to a particular platform (e.g., blog) or as audience members need to make
disclosures about their financial relationships with the manufacturer.216 For example, a
physician may receive funds for research or education from a manufacturer, but also be
commenting about the same manufacturer’s product or a different product independent
from this research or education. Given the increased transparency requirements
stemming from the Physician Payments Sunshine Act,217 manufacturers may need to
require that such physicians include disclaimers that they are being compensated for
the content or messages they generate or that their comments are not on behalf of the
manufacturer, but they may receive compensation from the manufacturer for unrelated
services. Lack of disclosure by physicians who contribute to interactive promotional
media platforms (e.g., chat rooms or blogs) may result in decreased patient trust, as
well as scrutiny from Centers for Medicare and Medicaid Services (CMS), the FDA,
and federal or state prosecutors. Such scrutiny may even occur under state consumer
protection laws, for a physician or other healthcare professional that fails to disclose
their financial interests. These added risks further demonstrate the need to closely
monitor manufacturers and corporate executives use of interactive promotional media.
D. Adverse Event Reporting
The FDA should articulate clear standards and guidance that instructs industry and
related stakeholders about adverse event218 reporting obligations in connection with
interactive promotional media. Several FDA regulations require companies to report
214
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adverse events associated with drugs to the FDA.219 Generally, manufacturers must
report to the FDA when they “become aware” of a drug, biologic, or medical device
adverse event (AE). The source of the adverse event information is generally not
determinative of a manufacturer’s obligation to report (e.g., physician versus patient
or consumer). Hundreds of millions of Americans are creating UGC on firm owned
and third-party websites, including information on symptoms, side effects, and other
health information. The FDA should carefully balance the need to report safety and
risk information with the undue burden on industry associated with constantly monitor
this kind of UGC on these platforms. The FDA should permit manufacturers to use a
flexible approach for monitoring and reporting AE’s on interactive promotional media,
and should articulate criteria that manufacturers could use to evaluate whether UGC
contains sufficient information for a manufacturer to become “aware” of an AE.
For example, on a monthly or quarterly basis, the FDA could recommend that
manufacturers monitor the interactive promotional media they have listed with the FDA
or risk information that is contained in the products PI. Manufacturers could incorporate
into their monitoring and surveillance for misinformation described above, key terms
or phrases that may indicate possible AE’s (e.g., hospitalization, emergency room,
etc.), which the FDA could provide examples of in future guidance. However, the FDA
should not require—at least in terms of AE reporting—manufacturers to monitor or
further investigate UGC that may reference commonly known side effects of a product
(e.g., nausea, sweating, fever, etc.). While a manufacturer may collect or monitor this
information voluntarily for other reasons (e.g., update labeling, learn of effects of drug
combinations or interactions), it would be too burdensome for industry to investigate
each instance in which a patient is having a side effect that is well known to the FDA
and the manufacturer, and does not amount to an AE. To ensure compliance with AE
reporting regulations, the FDA could ask manufacturers to initially submit a sample of
AE’s (e.g., ten percent) that the manufacturer has identified (and reported to the FDA
as required by the guidance) for the first month or quarter of each calendar year, rather
than requiring the manufacturer to submit every suspected AE.220 Thereafter, the FDA
could require companies to certify in their monthly post-marketing submissions that
the manufacturer is continuing to monitor and report AE’s consistent with their initial
submission.
While companies may need to invest significant resources to monitor such reported
AE’s,221 companies that follow posts may: (1) help reduce the number of AE’s by
getting early warnings of potential problems; (2) learn of any unexpected side effects
experience associated with a drug that can include death, a life-threatening condition, hospitalization
(initial or prolonged), disability or permanent damage, or a congenital anomaly or birth defect).
219
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in any specific populations; (3) get more information on the effects of various drug
combinations or interactions; and (4) identify new information to educate physicians.
Moreover, using interactive promotional media can expedite the process of capturing
post-marketing data, which is critical for determining if a drug’s label needs updating or a
black box warning, or if the manufacturer should recall the drug. Incorporating this kind
of system may build trust with patients and the FDA because it demonstrates a concern
for patient safety and a commitment to post-market surveillance. Manufacturers may
also want to restrict users from posting or commenting on personally identifiable health
information (PHI) or AE’s in public forums and should instead create a mechanism
within the interactive promotional media platform (or application) for patients to report
AE’s, similar to FDA’s MedWatcher Mobile App.222 Such measures may help protect
patient privacy and avoid the chance that users may request medical advice, including
requesting advice from healthcare professionals who may provide content on the
interactive platform.
E. Practical Considerations for Industry
The FDA’s recent guidance coupled with existing internet and social media campaigns,
offer several factors for companies to consider moving forward. When addressing
current interactive promotional media platforms as well as proposed new platforms,
companies may want to form cross-cutting groups of medical, legal, regulatory, and
marketing staff to ensure compliance with the FDA regulations and guidance.223 When
a manufacturer chooses to begin an online or social media presence, they should use
a wireframe224 to understand how the navigation and links for particular environments
of website content flow. The website should have a home page that displays certain
buttons (e.g., “Indications,”) that remain consistent and available throughout the mobile
presentation as a user navigates “through the different branded content options” or if the
user “decides to share . . . the branded content . . . .”225 Companies should also optimize
their websites for mobile device use to eliminate the need for consumers to scroll right
or left and to avoid making consumers zoom in to locate benefit or risk information. All
promotional materials should be on-label if branded, and companies should post the full
PI on any interactive promotional media for branded content or if the drug has a boxed
warning or REMS.226
When using websites and interactive promotional media, companies should be careful
about having pop-ups, scrolling information, banners, comments, or videos that
“causes [the] messages” of a disease awareness or help-seeking advertisement and a
reminder advertisement “to be linked together by the audience.”227 Such combined
communication—with information about the disease and the name of a drug—could
222
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constitute an advertisement that communicates a drug’s indication and efficacy, and
thus, without the required risk disclosures and other required information, could
cause the advertised product to be misbranded.228 In designing platforms that may
have overlapping messages or use different kinds of interactive promotional media,
companies should account for perceptual similarities and timing of presentation.229
However, manufacturers may have more flexibility in using different kinds of online
media because a recent FDA study found no evidence that consumer understanding
of risk information was effected by the “emotional (affective) tone of visual images
or the consistency of the visual images with the risk information on the screen
during the major statement.”230 Specifically, the FDA concluded that its Distraction
Study showed that “presenting risk information at the same time in text and in audio
improves consumers’ understanding of the risk information.”231 Despite this flexibility,
manufacturers designing interactive promotional media will have to pay close attention
to consumers understanding of “composite scores”232 in DTC advertisements. While
the FDA is surveying print advertisements, the Agency noted that such research “[may]
apply to any similar medium including static elements of Web sites.”233
Next, companies should update (or where necessary create) and implement internal
policies and procedures regarding the use of social media and the internet for DTC
advertisements. Manufacturer policies should outline: (1) the requirements and
standards for branded and unbranded social media activity; (2) how employees can
interact with company sponsored or created websites as well as third-party websites;
(3) who is responsible for monitoring and maintaining such websites; (4) who has the
ultimate authority over the website; and (5) potential scenarios when legal counsel
should be notified of consumer concerns. Moreover, companies should train employees
on all social media-related or internet policies,234 and set regular reviews to identify
weaknesses and areas for new or additional training, particularly given the constant
changes and updates to social media platforms and websites. In light of the AMARC
letter, this training is particularly important to prevent employees who have control
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over Facebook or related social media platforms from “liking” content not created
by the company, which may render it promotional and suggest to the FDA that there
is some form of manufacturer control, influence, or further dissemination, even if an
independent third-party created the content.
In addition, companies may want to set standard response times for comments or
questions posted by users of websites and publicize such information regarding
standardized response times. When responding to comments, companies should try to
use language that patients can understand to avoid confusion.235 Internal policies may
also want to address: (1) use of rollovers to help define complicated medical terms; (2)
use of images of real people, not actors, to tell compelling stories that highlight drug
benefits, as long as these stories comply with FDA regulations; (3) use of callouts to
highlight key brand messages; and (4) regular update of the website content, especially
when there is news on a product or health condition to entice patients to come back to
the website.236
F. The FDA’s Implementation of Interactive Promotional Media Standards
The FDA’s future guidance should take into account the various aspects of social media
(e.g., type of medium) and the rapid advances and updates that social media technology
and platforms undergo. For example, similar to the FDA’s regulations and guidance
governing current good manufacturing practices (cGMP) for drugs and devices, the
FDA should ensure that social media and internet guidance reflect the same “current”237
status. Specifically, the FDA should establish a streamlined process or mechanism by
which the Agency can regularly update interactive promotional media guidance and
standards or establish so called “current Good Social Media Practices” (cGSMP).
To accomplish this goal, the FDA could convene an Advisory Committee on Interactive
Promotional Media, which could include members from the pharmaceutical and social
media industry, the FDA, patients, and consumers. This Committee could meet on a
quarterly basis, or more frequently as needed, to address key changes affecting interactive
promotional media and meetings would be open to the public. The Committee could
also propose specific topics for the FDA to research regarding interactive promotional
media to determine its affect on consumers. For example, the FDA could study the
effectiveness of conveying drug risk information through hyperlinks. The Committee
could make recommendations to OPDP, such as those listed above, that the FDA
could adopt after public notice and comment, unless OCC or the FDA’s Office of the
Commissioner objects or a Citizen’s Petition238 is filed. The FDA could publish the new
changes immediately on its website and social media platforms, as well as in the Federal
235

Amy Norton, Web info on prostate cancer tough to understand, Reuters (Oct. 25, 2012), http://
www.reuters.com/article/2012/10/25/us-prostate-cancer-idUSBRE89O1G620121025.
236

Richard Meyer, Why Branded Websites Are So Important to Pharma, WorldofDTCMarketing.
(Nov. 9, 2012), http://worldofdtcmarketing.com/why-branded-websites-are-so-important-topharma/prescription-drug-dtc-marketing/.
com
237

See Food and Drug Admin., Facts About Current Good Manufacturing Practices (cGMPs),
FDA.gov (May 2, 2013), http://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/
ucm169105.htm. The “c” in cGMP stands for “current.” Id.
238

See 21 C.F.R. § 10.30 (2013).

One Click Away From Untangling the Web

37

Register. The FDA could also create a list-serve for stakeholders to register and receive
notification of these types of updates and changes.
This process could appease potential concerns from industry or consumers because
groups would have several mechanisms to participate in the process to update social
media and internet guidance and standards. If the FDA is unable to create this
Committee, due to regulatory hurdles, Congress could authorize its creation by statute
in the next User Fee Act negotiations239 or through separate user fees for interactive
promotional ideas, which Congress considered doing in the past. Companies may now
be willing to pay user fees given the significant demand for clarity in using interactive
promotional media, the fear of enforcement, the tremendous potential such tools have
for public health and marketing, and the negative effects that accompany a continued
lack of companies presence online.

VII. CONCLUSION
With social media guidance amongst “the highest of FDA’s priorities,”240 companies
must begin to prepare their advertising and marketing departments accordingly,
particularly with the FDA’s first Guidance, and three more on the horizon in 2014. This
includes forming employee teams comprised of individuals with regulatory, marketing,
legal, and medical experience to help the company navigate the current regulatory
environment and learn how to market their products to consumers using interactive
promotional media. Given the rapid increase in social media users, the benefits
associated with company use of such platforms likely outweigh the risks and regulatory
hurdles discussed in this article.
While there may be legal or regulatory consequences, “[t]he monetary costs of gaining
access to social media are negligible, whereas the benefits associated with its use—
increased brand awareness, greater market reach, quicker and more comprehensive
feedback—are endless.”241 Furthermore, continuing to delay social media use may
only harm patients further because companies will be unable to fight the continued
rise of third-party misinformation.242 In addition, social media allows companies to
grow new markets, “gain insight about new products, develop more targeted marketing
practices,”243 and better understand how factors such as drug availability, packaging,
and pricing could be affecting usage patterns. Understanding the regulatory landscape
of interactive promotional media will also be critical for companies to gain access to
patients using mobile medical applications by sending effective patient educational
information through general health and wellness applications, as well as those
applications designed for medication adherence and drug-interaction warnings. Until

239

See Food and Drug Admin., User Fees, FDA.gov (Jan. 10, 2014), http://www.fda.gov/
ForIndustry/UserFees/default.htm.
240

Slajda, supra note 192.

241

Liu, supra note 122.

242

Brian Reid, The 5 Consequences of the Lack of FDA Social Media Guidance, Common Sense
(Dec. 8, 2011), http://blog.wcgworld.com/2011/12/the-5-consequences-of-the-lack-of-fda-socialmedia-guidance.
243

38

Id.

Health Law & Policy Brief • Volume 8, Issue 2 • Spring 2014

the FDA finalizes guidance on the use of links and character space limitations on such
applications, however, much uncertainty remains in this area.
Because many patients use interactive promotional media to share and obtain
information about drugs, the FDA’s future guidance should enable companies to use
these platforms in ways that can advance public health by disseminating reliable and
accurate information about their products, without imposing undue regulatory burdens
and requirements that infringe upon First Amendment rights. Ultimately, ensuring
that patients and consumers can receive benefit and risk information about specific
treatments and other disease information through interactive promotional media will
accomplish the FDA’s goals and purpose as a public health agency by informing patients
and enhancing their health and safety.
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